GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Eric Padron(Moffitt Cancer Center), Pearlie K. Epling‐Burnette(AbbVie (United States)), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Jeffrey E. Lancet(Cornell University), Sateesh Kunigal(University of Illinois Urbana-Champaign), Kathy L. McGraw(National Institutes of Health), Alan F. List(TE Laboratories (Ireland)), Jeffrey S. Painter(University of South Florida), Eun Hee Kim(Ulsan College), Jessica M. McDaniel(University of South Florida), Mark Baer, Geoffrey Yarranton, Adam W. Mailloux(University of South Florida), Christopher Bebbington(Curtin University), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 155
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k